Video

Dr. Shore on VISION trial and future of PSMA-targeted agents in prostate cancer

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Neal D. Shore, MD, discusses the phase 3 VISION trial, in which adding the targeted radioligand therapy 177Lu-PSMA-617 to standard of care (SOC) led to a nearly 40% reduction in the risk of death versus SOC alone in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer. Shore, who is medical director of the Carolina Urologic Research Center, also provides insight on the next steps with PSMA-targeted agents in prostate cancer.

      © 2025 MJH Life Sciences

      All rights reserved.